FDA authorizes bivalent COVID-19 boosters for children as young as 6 months

The Food and Drug Administration (FDA) last week announced it has expanded the emergency use authorization for the bivalent COVID-19 booster to include children between the ages of 6 months and 5 years. With this announcement, children older than 6 months who have received the primary two-dose coronavirus vaccines from Moderna are now eligible to receive the bivalent booster specifically designed to protect against omicron subvariants of the virus. Read more from The Hill here.